Targeted therapy consists of BRAF inhibitors (e.g., dabrafenib), MEK inhibitors (e.g., trametinib), combination of BRAF and MEK inhibitors, BCR-ABL tyrosine kinase inhibitors (e.g., imatinib), or tumor agnostic treatment (e.g., larotrectinib). Here, MAP2K7 is linked to neoplasm.